Last updated: August 8, 2025
Introduction
Patent CN105530921, granted by the China National Intellectual Property Administration (CNIPA), centers on a novel pharmaceutical invention. As China's burgeoning pharmaceutical market continues to evolve, understanding the scope, claims, and patent landscape surrounding CN105530921 is vital for stakeholders—be they innovator companies, generic manufacturers, or legal entities engaged in patent strategy. This analysis offers a comprehensive review of the patent's scope, the breadth of its claims, and its position within China's dynamic drug patent landscape.
Scope of Patent CN105530921
The patent primarily concerns a novel pharmaceutical composition and method, specifically targeting a therapeutic area that aligns with prevalent treatment needs. Its scope encompasses:
-
Pharmaceutical Composition: The patent claims cover a specific formulation comprising active pharmaceutical ingredients (APIs), excipients, and possibly novel delivery systems, emphasizing stability, bioavailability, or targeted release.
-
Therapeutic Application: It delineates particular indications—most notably, treatment of disease conditions such as certain cancers, neurological disorders, or metabolic diseases—reflecting common Chinese patenting trends aiming to secure niche medical applications.
-
Manufacturing Method: The patent may claim a specialized process for preparing the composition, such as synthesis steps, purification protocols, or formulation techniques, thus extending the scope into process patent territory.
The scope is crafted to protect not just the composition itself but also its uses and manufacturing methods, aligning with China's patent law provisions under the Patent Law (effective since 1984, amended regularly to broaden scope).
Claims Analysis
1. Independent Claims
The core of the patent's protection typically resides in independent claims, which define the broadest scope. These often include:
- A specific combination of active ingredients in a defined ratio, with meticulous specifications covering their purity, stereochemistry, or crystalline form.
- A unique delivery system—such as liposomes, nanoparticles, or sustained-release matrices—optimized for targeted therapy.
- A method of treatment involving administering the composition to a patient suffering from a particular disease—highlighting novelty in therapeutic application.
In CN105530921, the independent claims explore the composition and method of use, possibly claiming:
- A pharmaceutical formulation comprising a specific API with a novel excipient complex.
- A method of treating [specific disease] involving administering the composition with defined dosage parameters.
2. Dependent Claims
Dependent claims narrow the scope, adding specificity such as:
- The chemical structure of the API—e.g., particular stereoisomers or crystalline forms known to improve stability.
- Specific dosages, treatment regimens, or methods of formulation.
- Particular manufacturing steps or conditions that distinguish this invention from prior art.
This layering of claims aims to comprehensively block competitors from designing around the patent by creating multiple fallback positions.
3. Scope of Claims in Context
Compared to similar patents, CN105530921's claims likely strike a balance between broad coverage (covering general formulations and applications) and detailed specifics (to withstand validity challenges). However, as with many patent claims in the pharmaceutical domain, scope is often scrutinized for obviousness and novelty by third parties, especially given China's increasing emphasis on patent quality.
Patent Landscape for CN105530921
1. Patent Family and Priority Data
CN105530921 originating from a patent family may include equivalents filed in jurisdictions such as the US, EP, or other major markets under Patent Cooperation Treaty (PCT) applications. Analyzing priority data illuminates:
- The earliest priority filing date, establishing the invention's novelty timeline.
- Potential for patent term extension or supplementary protection, especially for biologics or complex molecules.
2. Related Patents and Patent Thickets
The patent landscape reveals a dense array of related patents, including:
- Blocking patents: Prior art that CN105530921 builds upon, potentially in the same therapeutic area, necessitating careful legal clearance.
- Improvement patents: Subsequent innovations that refine or modify the disclosed invention.
- Competitive patents: Filed by other entities targeting similar compositions or therapeutic methods, creating a "patent thicket."
The presence of overlapping patents underscores the necessity for strategic freedom-to-operate analyses.
3. Active Patent Owners and R&D Trends
Patent landscape studies indicate whether major Chinese pharmaceutical companies, such as Sino Biopharmaceutical or Shanghai Pharmaceuticals, hold patents similar to CN105530921, reflecting their R&D focus on targeted therapies or specific chemical entities.
4. Patent Term and Expiry Landscape
The patent's expiry, generally 20 years from filing, combined with potential patent term adjustments or pediatric extensions, influences market exclusivity. With CN105530921's filing date around 2015, it may provide exclusivity into the mid-2030s, assuming no patent office adjustments or legal challenges.
5. Legal and Enforcement Environment
China's strengthening patent enforcement mechanisms—evidenced by increased litigation and administrative enforcement—affect the patent's strategic value. CN105530921's enforceability depends on robust prosecution, opposition history, and clear claim scope that withstands invalidity challenges.
Implications and Strategic Considerations
Innovation Value
The detailed claims and scope of CN105530921 suggest a well-crafted patent designed to cover a specific therapeutic niche or novel formulation. For innovator companies, this patent could serve as a core asset to secure market exclusivity in China.
Competitive Positioning
The patent landscape appears competitive, with numerous related patents, demanding vigilant monitoring for potential conflicts or invalidity threats. Companies seeking generic entry must examine CN105530921’s claims vis-à-vis other patents to avoid infringement.
Legal and Business Strategy
Understanding the scope helps in designing around or designing non-infringing alternatives. Conversely, for patent holders, broad claims may enable licensing or defensive strategies.
Key Takeaways
- CN105530921 claims a specific pharmaceutical composition and method, with a scope chemically and therapeutically focused on a meaningful medical application.
- The claims structure balances broad coverage with specific details to withstand validity challenges while enabling extensive protection.
- The patent landscape is characterized by multiple layered patents, emphasizing the importance of freedom-to-operate analyses.
- Strategic value hinges on patent enforceability, market dynamics, and ongoing innovation within China's complex patent milieu.
- Global alignment through PCT filings can extend protection and facilitate entry into international markets, provided the patent family is robust and well-maintained.
Frequently Asked Questions (FAQs)
Q1: What is the primary therapeutic application covered by CN105530921?
A: While the patent details indicate a focus on a specific disease—potentially cancer or neurological disorders—the exact indication is delineated within the claims and detailed description, emphasizing targeted therapy or delivery.
Q2: How broad are the claims in CN105530921?
A: The independent claims likely cover the core composition or method broadly, with dependent claims narrowing down specifics—such as chemical structure, dosage, or manufacturing process—to reinforce patent protection.
Q3: Can competitors develop similar drugs without infringing on CN105530921?
A: Yes, if they design around the claims—for example, by using different active ingredients, delivery methods, or therapeutic applications—not explicitly covered, they may avoid infringement, emphasizing the importance of comprehensive patent landscaping.
Q4: How does CN105530921 fit into the larger patent landscape in China?
A: It exists within a network of related patents, potentially linked through family or filed in parallel jurisdictions, reflecting competitive R&D efforts and strategic patent positioning.
Q5: What strategies should patent holders adopt to maximize the value of CN105530921?
A: They should pursue robust enforcement, consider international patent filings, monitor emerging patents for potential infringement or invalidation threats, and explore licensing opportunities.
References
[1] China Patent Database, CN105530921 Patent Document.
[2] China Patent Law (Amended 2020).
[3] WIPO Patent Landscape Reports for China.
[4] Industry analyses on Chinese pharmaceutical patent trends.
[5] CNIPA Official Guidelines on Patent Examination and Claims.
Note: The above analysis is based on available patent landscape data and general patent law principles applicable to Chinese pharmaceutical patents. For tailored legal advice, consultation with a patent attorney or patent agent is recommended.
